TXA2/TP Inhibitor
- 1
-
Treprostinil
0 ImagesSynonyms: UT-15Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.
-
Ginsenoside Ro
0 ImagesSynonyms: Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V
-
(Z)-Isbogrel
0 ImagesCat. No.: HY-119890ACAS No.: 89667-39-0Synonyms: (Z)-CV-4151(Z)-Isbogrel ((Z)-CV-4151) is a potent thromboxane A2 (TxA2) synthase inhibitor with an IC50 of 0.9 nM. (Z)-Isbogrel inhibits serum TxB2 production, with an ED50 of 0.01 mg/kg upon intravenous administration and an ED50 of 0.05 mg/kg upon oral administration in rats, and it exhibits no PAF receptor antagonistic activity. (Z)-Isbogrel can be used in research related to cardiovascular and cerebrovascular diseases.
-
NP-1815-PX sodium
0 ImagesNP-1815-PX sodium is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC50 of 0.26 μM against human P2X4 receptors. NP-1815-PX sodium specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX sodium selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX sodium not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX sodium exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX sodium is used in studies related to asthma and inflammatory bowel disease (colitis).
-
Ozagrel
0 ImagesSynonyms: OKY-046Ozagrel (OKY-046) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel can be used for the study of ischemic stroke, asthma and thromboembolic diseases.
-
Ozagrel hydrochloride
0 ImagesSynonyms: OKY-046 hydrochlorideOzagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases.
-
Picotamide
0 ImagesPicotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases.
-
Ozagrel sodium
0 ImagesSynonyms: OKY-046 sodiumOzagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases.
-
Trapidil
0 ImagesSynonyms: AR-12008Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury.
-
Wy 27569
0 ImagesCat. No.: HY-105866CAS No.: 103417-69-2Wy 27569 is an orally active vascular selective calcium channel blocker that can effectively lower blood pressure. Wy 27569 is a thromboxane synthase inhibitor that can reshape prostaglandin balance, reduce pro thrombotic TXA2, and increase anti thrombotic PGI2. Wy 27569 can be used for research on cardiovascular diseases such as hypertension and angina.
-
CV-6504
0 ImagesCat. No.: HY-19064CAS No.: 117574-40-0CV-6504 is a dual inhibitor of TXA2 synthase and 5-lipoxygenase. CV-6504 can scavenge ROS and exhibit antitumor activity. CV-6504 can be used for the researches of cancer, inflammation and cardiovascular disease.
-
KT2-962
0 ImagesCat. No.: HY-19129CAS No.: 129648-96-0KT2-962 is a thromboxane A2 (TXA2) receptor antagonist and potent hydroxyl radical scavenger (IC50=500 nM). KT2-962 reduces myocardial infarct size and ventricular fibrillation. KT2-962 demonstrates cardioprotective effect in a canine ischemia/reperfusion model. KT2-962 is promising for research of myocardial ischemia-reperfusion injury and TXA2-mediated vascular diseases.
-
Chinoin 127
0 ImagesCat. No.: HY-105977CAS No.: 71392-29-5Chinoin 127 is a non anesthetic analgesic agent with strong anti-inflammatory activity. Chinoin 127 shows potent analgesic effect in the hot plate test, Randall Selitto test, and torsion test.
-
E-6700
0 ImagesCat. No.: HY-19166CAS No.: 144562-61-8E-6700 is an inhibitor of 5-LO and TXA2 synthetase, with IC50s of 16.3 μM and 0.026 μM respectively. E-6700 inhibits LTB4 and TXB2 production. E-6700 can be used for antiinflammatory research.
-
KC-764
0 ImagesCat. No.: HY-100484CAS No.: 94457-09-7KC-764 is an orally active, reversible cyclooxygenase inhibitor with relative selectivity for platelet cyclooxygenase. KC-764 inhibits platelet thromboxane A2 (TXA2) production and platelet aggregation, with IC50s of 0.23 μM and 26 nM, respectively. KC-764 can be used for the research on antiplatelet and recurrence prevention in ischemic stroke.
-
CAY10535
0 ImagesCat. No.: HY-118014CAS No.: 945716-28-9CAY10535 is a FP and TP receptor inhibitor and can be used for research of cardiovascular diseases.
-
Etersalate
0 ImagesCat. No.: HY-101606CAS No.: 62992-61-4Synonyms: Eterylate; EtherylateEtersalate inhibits platelet function and decreases thromboxane A2 (TXA2) levels.
-
BM567
0 ImagesCat. No.: HY-124150CAS No.: 284464-77-3BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A2 receptor (TXR) antagonists and thromboxane A2 synthase (TXS) inhibitors, with IC50s of 1.1 and 12 nM, respectively.
-
Ozagrel hydrochloride (Standard)
0 ImagesSynonyms: OKY-046 hydrochloride (Standard)Ozagrel hydrochloride (Standard) is the analytical reference standard of Ozagrel hydrochloride (HY-B0428B). Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases.
-
CGS 15435
0 ImagesCat. No.: HY-100283CAS No.: 95853-92-2CGS 15435, a potent thromboxane (TxA2) synthetase inhibitor with an IC50 of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI2 synthetase and lipoxygenase enzymes.
- 1
